-
Xinda Bio refinanced HK$4.671 billion through the distribution
Time of Update: 2021-03-09
According to the announcement, a total of 52 million shares of Xinda Bio have been successfully issued by the distribution agent to not less than six contractors in accordance with the terms and conditions of the rights issue agreement, with a distribution price of HK$90.90 per share, resulting in a net proceeds of about HK$4.671 billion.
-
Work injury protection expansion! China will promote the protection of occupational injury of new professionals
Time of Update: 2021-03-09
the end of 2020, more than 30.14 million poor elderly people receive basic old-age insurance treatment on a monthly rate.
-
Analysis: "Change" and Its "Control" under the GMP System
Time of Update: 2021-03-09
It is normal for drugs to change during the production process. Even in developed countries with relatively high drug research and development capabilities, it is very common for a variety to change
-
The original price of 19,000 fell to 648 such medical supplies began to purchase
Time of Update: 2021-03-09
1, a maximum drop of 95%, began to implement January 10, according to Henan News Broadcasting, the results of the crown stent belt purchase has been officially landed in Henan Province, located in Zhengzhou City, Huazhong Outside Hospital intervention operating room, patients officially use the reduced price of the stent - from the original price of 19,000 yuan to 648 yuan.
-
Production and sale of inferior drug ginseng injections A pharmaceutical company is punished
Time of Update: 2021-03-09
, Ltd. because of the production and sale of clams that do not meet the drug standards, by the Three Gorges Public Inspection and Testing Center inspection (report number: 2020 medicine 0449), Wuhan Mindetang Chinese medicine tablets Co.
-
Under the new edition of the pharmacopeia, the market demand for 33 agricultural residue detection items of Chinese medicine has skyrocketed
Time of Update: 2021-03-09
The pass rate of Chinese medicine drink tablets has been improved in Chinese herbal medicine, Chinese medicine tablets agricultural residue inspection pass rate, a number of third-party testing platform revealed the information figures are relatively close, according to their feedback, in recent times the detection situation, in fact, the relevant plant-based medicinal herbs and Chinese medicine tablets agricultural residues exceeded the standard phenomenon, is not our industry in the past worried about as serious.
-
Pharmaceutical Bio's 150 million euro acquisition of Bayer Biopharmaceity's original liquid plant
Time of Update: 2021-03-09
MFG19 will join forces with the Biologics Plant (DP7) in Leverkusen, Germany, to help Pharmaceuticals provide commercial production services.
MFG19 and DP7 are expected to go into production in 2021, providing strong support for the European production supply chain for pharmaceutical products.
-
"Chinese medicine a brother" status changes? Sales of hepatitis drug kingpy market have skyrocketed again
Time of Update: 2021-03-09
Tablets: Drug "Luxury" Figure 2: Net profit situation of Tablets Units: RMB billion) Source: Annual report, individual stock research report from the performance growth rate, Tablets In recent years significantly stronger than Yunnan White Medicine: Tablets 2016-2020 net profit growth rate of 14.88 percent, respectively 50.53%, 41.62%, 20.25% and 21.27%, respectively, and Yunnan White Pharmaceutical's net profit growth in 2016-2019 was 5.38%, 7.71%, 5.14% and 19.75% (no relevant data available for 2020).
-
A brief analysis of the change of the location of pharmaceutical enterprises in the context of industrial digitalization to make site selection more efficient!
Time of Update: 2021-03-09
Enterprise location decision-makers to obtain site selection clues, the need for continuous field visits, by the cost of time and cross-regional space constraints, coupled with the biopharmaceutical industry's unique complex approval procedures, resulting in the vast majority of pharmaceutical companies in the traditional site selection decision-making will be more biased towards standardized supporting parks.
-
Haier Bio intends to sell its stake in the U.S. company
Time of Update: 2021-03-09
According to the announcement, Haier Bio recently received notice from Mesa, a U.S. subsidiary, that Thermo Fisher intends to acquire a full stake in Mesa and has signed a merger agreement that applies to U.S. Delaware law.
-
First Sound Pharmaceuticals has welcomed two key products in the third quarter
Time of Update: 2021-03-08
These include the company's 13 years of independent research and development with independent intellectual property rights of a class 1 innovative drug Ida Lafeng right alcohol injection with a thick solution, approved in China through the priority review process, adaptive disease for stroke patients.
-
Ali Health: E-commerce is still picking the big beam Internet medical growth fast
Time of Update: 2021-03-08
On the evening of May 27th, Ali Health, which combines pharmaceutical e-commerce, Internet medical, consumer medicine, smart healthcare and other businesses, released its 2020 financial results, which showed revenue of 9.6 billion yuan, up 88.3% YoY, and gross profit of 2.23 billion yuan, up 67.6% YoY, with a loss of 15.7 million yuan, down 82.9% YoY.
-
Concino owns full rights to the production and commercialization of Ad5-nCoV
Time of Update: 2021-03-08
June 8, Concino Bio issued a clarification announcement, noting the company's stock price fluctuations and some media reports about the restructuring of the new coronavirus vaccine (Ad5-nCoV) produced in Guizhou.
-
The actual controller and controlling shareholder of Susser Bio are involved in the lawsuit
Time of Update: 2021-03-08
December 7, Seselsu Bio issued an announcement regarding litigation involving actual controllers and controlling shareholders. According to the announcement, on October 29, 2020, SSE disclosed the "A
-
Ering Pharmaceuticals Semi-Annual Report Announces 50.35% YoY Increase in Operating Income
Time of Update: 2021-03-08
In the research and development and production of patented Chinese medicine at the same time, Toling Pharmaceuticals to promote "zero-level prevention", and actively lay out the large health industry.
-
Shi Jian Bio completed tens of millions of yuan of Pre-A round financing
Time of Update: 2021-03-08
ShiJian Bio's product positioning is global Best/First-in-Class, product pipeline both pharmaceutical and market potential, the company has also built a global wide range of business cooperation to expand the network, with a number of the world's top Biotech companies to achieve business and strategic cooperation.
-
SSO Bio announced the completion of nearly RMB300 million round D financing
Time of Update: 2021-03-08
The International Multi-Center Clinical Phase III Trial (ENGINE Study) of DB102 (enzastaurin) for first-line treatment of diffuse large B-cell lymphoma (DLBCL) has been completed in all patient groups.
-
A large number of medical representatives or ushered in change
Time of Update: 2021-03-08
In this regard, Chongqing Doputai Pharmaceutical Promotion Minister Zhao Jiazhen to Saibai Blue analysis: for this kind of participating national collection of varieties, pharmaceutical companies have no room to do the relevant high-density customer and cost support, and related pharmaceutical representatives to carry out a transformation, either to professional academic promotion, commercial insurance transformation, or to seek some other way out.
-
Paige Bio completes financing to advance the development of innovative drug pipelines for chronic diseases
Time of Update: 2021-03-08
Paige Bio is the leading domestic biotechnology company focused on the development of new drugs for chronic diseases, and has a number of clinical stage products, we are very optimistic about the company's layout and advantages in the field of the disease.
-
Legendary creature surges 60% on first day of U.S. IPO
Time of Update: 2021-03-08
Car-T products are expected to be listed in the U.S. by the end of the year public information shows that Nanjing Legendary Bio was founded in 2014 as a global clinical phase biopharmaceutical company dedicated to the discovery and development of new cell therapies for oncology and other adaptations.
